Looming competition from the east
29/11/19 -"A number of initiatives taken by the Chinese government to strengthen its pharmaceutical sector have started to bear fruit – Biogene’s ‘zanubrutinib’ became the first innovative drug by a Chinese ..."
Pages
66
Language
English
Published on
29/11/19
You may also be interested by these reports :
19/08/26
The Q2 sales were ahead of expectations, though profitability was in line with consensus. Strong growth for the migraine drug Vyepti, ...
18/08/26
The H1 results exceeded expectations, backed by strong growth in Bimzelx and other key products. Consequently, the management revised the full-year ...
17/08/26
The Q2/H1 results surpassed expectations, again driven by the Biosimilars growth engine, as Generics posted muted growth. Also, the management ...
14/08/26
The Q2 results exceeded consensus estimates, driven by a healthy showing from Crop Science, whereas the growth for the other two businesses was ...